Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Chen Jiang(Union Hospital), Daniel L. Bowers, Kouros Owzar(Duke University), Alan P. Venook(University of California, San Francisco), Andrew B. Nixon(Duke University), Federico Innocenti(AbbVie (United States)), Herbert I. Hurwitz(Duke Medical Center), Mark D. Starr(Duke Medical Center), Donna Niedzwiecki(Duke University), J. Chris Brady, Herbert Pang(Duke University), Ace J. Hatch(Duke Medical Center), Jingquan Jia(Duke Medical Center), Alexander B. Sibley(Duke University)
Cited by 7
Related Papers
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k
Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival
|Hepatology|2001|2.3k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998